Agilent Technologies, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended October 31, 2023. Although the request labels the period “2023 Q4,” this filing reports full-year results, not standalone fourth-quarter results. Agilent provides instruments, software, services and consumables for life sciences, diagnostics and applied chemical markets.
Financial performance
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $6.833 billion | $6.848 billion | Approximately flat |
| Gross margin | 50.7% | 54.4% | Down 3.7 percentage points |
| Operating income | $1.350 billion | $1.618 billion | Down 17% |
| Operating margin | 19.8% | 23.6% | Down 3.8 percentage points |
| Net income | $1.240 billion | $1.254 billion | Down 1% |
| Diluted EPS | $4.19 | $4.18 | Up slightly |
| Cash from operating activities | $1.772 billion | $1.312 billion | Up $460 million |
| Capital expenditures | $298 million | $291 million | Up $7 million |
| Cash and cash equivalents | $1.590 billion | $1.053 billion | Up $537 million |
Products revenue fell 3% to $5.051 billion; services and other revenue rose 7% to $1.782 billion. Operating cash flow less capital expenditures was approximately $1.474 billion, calculated from the filing’s figures.
Segments
| Segment | FY2023 revenue | Year-over-year change | FY2023 operating income |
|---|---|---|---|
| Life Sciences and Applied Markets | $3.856 billion | Down 4% | $1.116 billion |
| Diagnostics and Genomics | $1.409 billion | Up 1% | $296 million |
| Agilent CrossLab | $1.568 billion | Up 8% | $463 million |
CrossLab growth and services revenue helped offset weaker instrument and product demand. Segment operating income excludes certain unallocated costs; it should not be equated with consolidated operating income.
Debt, liquidity and capital allocation
- Balance-sheet long-term debt was $2.735 billion; cash and cash equivalents were $1.590 billion. No commercial paper or revolving-credit borrowings were outstanding at year-end.
- The $600 million term loan carried a 6.22% weighted-average interest rate at year-end and matures in April 2025. Agilent prepaid $120 million of it on December 14, 2023, after year-end.
- Agilent had a $1.5 billion revolving credit facility, with up to $750 million of incremental facilities, and a separate $300 million uncommitted money-market line. Management said available liquidity and expected operating cash flows should meet requirements for at least the next 12 months and beyond.
- FY2023 cash dividends were $265 million ($0.900 per share). The board declared a subsequent quarterly dividend of $0.236 per share, payable January 24, 2024.
- Agilent repurchased 4.6 million shares during FY2023 for approximately $575 million, including excise tax. The $2.0 billion repurchase authorization had approximately $1.524 billion remaining at year-end.
Material changes and unusual items
- Revenue was nearly flat after 8% growth in FY2022. Foreign exchange reduced FY2023 revenue growth by approximately 2 percentage points.
- Management attributed weaker performance primarily to lower demand in China and pressure on customer capital spending, particularly in pharmaceuticals and Life Sciences and Applied Markets. China revenue was $1.383 billion, down from $1.499 billion.
- Consolidated gross margin and operating margin were materially affected by impairment charges tied primarily to exiting Resolution Bioscience. The filing reports $277 million of FY2023 long-lived-asset impairment charges; MD&A identifies $253 million as the amount significantly affecting consolidated gross margin. These measures reflect different disclosures in the filing.
- Agilent agreed to divest Resolution Bioscience for $50 million and recorded a $43 million gain on divestiture. It also paid $65 million in contingent consideration related to that acquisition during FY2023.
- FY2023 net income included a notably low 7.4% effective tax rate, compared with 16.6% in FY2022. The FY2023 rate benefited from tax items including a $104 million federal tax benefit related to the realized divestiture loss, a $41 million foreign-derived intangible income benefit and a $30 million release of U.S. tax reserves.
Outlook, risks and contingencies
- No specific consolidated revenue or EPS guidance for FY2024 is provided in the supplied filing text. Management anticipated a challenging near-term macroeconomic environment, particularly in China, pressure on customer capital spending and continued inflation, while expressing optimism about longer-term growth in key markets. It cited targeted pricing and cost savings as mitigation measures.
- A FY2023 restructuring plan targets about 400 employee reductions (approximately 2% of the workforce) and facility consolidation. Agilent recorded $46 million of costs, expects approximately $80 million in annual cost-of-sales and operating-expense savings when completed, and expects substantial completion by the end of FY2024.
- FY2024 capital expenditures were expected to be approximately $400 million. Agilent also announced an approximately $725 million expansion of its Frederick, Colorado nucleic-acid therapeutics manufacturing capacity; some investment may qualify for reimbursement incentives.
- Key disclosed risks include economic weakness and customer budget changes; China and broader geopolitical or trade uncertainty; foreign-exchange and inflation exposure; supply-chain and inventory forecasting risks; competition and product-development execution; regulatory and privacy compliance; cybersecurity; environmental liabilities and facility disruptions; pension-market exposure; tax uncertainty; and debt covenant or refinancing risks.
- Agilent reported no pending legal matters it believed reasonably possible of having a material impact. It also reported no material off-balance-sheet arrangements. The independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting; inventory valuation was identified as a critical audit matter.
Most important facts for investors to verify
- Whether customer capital spending and China demand recover, and whether FY2023 weakness persists in Life Sciences and Applied Markets.
- How much of the margin decline reflects the Resolution Bioscience impairment and restructuring versus underlying operating performance.
- Progress toward the restructuring’s approximately $80 million annual savings target and the timing and returns of the Colorado capacity expansion.
- The sustainability of earnings and cash generation given the unusually low FY2023 tax rate and the filing’s identified inventory-estimation sensitivity.
- Debt repayment plans and the effect of the term loan’s variable rate, alongside continued share repurchases, dividends and capital investment.